The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer

Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer

March 29, 2017 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Conclusion: Immune checkpoint inhibitors have revolutionized the treatment of cancer. Despite their benefits, they can cause severe AEs that limit their full therapeutic benefits and result in considerable morbidity and mortality. No clear evidence exists regarding whether aggressive treatment of AEs may impair the benefits of immunotherapy. Additional studies are needed to determine how to adequately control and manage AEs without a detrimental effect on tumor immunity.

You Might Also Like
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • The Latest Data on Cancer Immunotherapy’s Interaction with Autoimmunity

Because of concerns of enhanced inflammation and autoimmunity, patients with cancer and prior autoimmune disorders have typically been excluded from receiving checkpoint inhibition therapy. However, until more precise estimates of the potential harms are available, careful consideration of the risks and benefits and individual preferences need to be considered when making decisions regarding therapy for patients with cancer and autoimmune disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Read the full article.

Excerpted and adapted from:
Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 2017 Apr;69(4):tktk.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: Arthritis & Rheumatology, Cancer, Checkpoint Inhibitors, immunotherapy

You Might Also Like:
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • The Latest Data on Cancer Immunotherapy’s Interaction with Autoimmunity
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)